Gilead is collaborating with Nucleai to use AI tissue analytics in its oncology drug development.
This supports its diversification beyond HIV into oncology.
The collaboration has already produced candidate biomarkers and new biological insights.
What happened
Nucleai announced an ongoing translational research collaboration with Gilead Sciences, using AI-driven tissue analytics on large H&E and IHC slide datasets to support Gilead’s global antibody-drug conjugate clinical development programs across multiple oncology indications. The work has already produced candidate spatial biomarkers and fresh biological insights.
Why it matters
This collaboration supports Gilead’s efforts to build a credible second growth pillar in oncology beyond its HIV cash flows. It aims to sharpen biomarker selection for current and future antibody-drug conjugates, and could help standardize biomarker assessment and better link tumor biology to clinical outcomes in precision oncology.
What to watch
Gilead’s near-term focus remains on Trodelvy’s first-line breast cancer rollout and on pricing and policy pressure in HIV. The Nucleai work plugs into the ambition to make Trodelvy a more central oncology asset, but it does not remove execution risk or market access challenges.
Ask the AI about this article →
Gilead’s investment narrative has long depended on HIV cash flows funding a second growth pillar in oncology. The Nucleai collaboration is a modest step in that direction, aiming to sharpen biomarker selection for antibody-drug conjugates. This aligns with recent positive regulatory decisions for Trodelvy in first-line triple negative breast cancer, making it a more central oncology asset. However, the collaboration does not, by itself, address execution risks or market access challenges in oncology, nor does it change near-term focus on HIV pricing pressures. The bullish analysts’ forecasts of $38.1 billion revenue and $12.7 billion earnings by 2029 are far more optimistic than the baseline narrative, and the Nucleai news either strengthens that case or highlights how much still needs to go right for those forecasts to hold.
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytime
Ask AI anything about this article. Q&As are published on this page for other readers too.
Nvidia is reportedly in discussions to invest in AI startup Perplexity as part of a funding round that would v…
SK Hynix is pushing beyond HBM (high-bandwidth memory, a key component in AI chips) to two new areas: HBF and…
Anthropic's Claude AI service is currently experiencing an outage, as indicated by the article title
ITmedia's ICT Research Division tested ChatGPT, Gemini, and Claude Sonnet 5 in July 2026
Taiwan prosecutors indicted nine people, including employees of Nvidia and Super Micro, for allegedly exportin…
Snowflake introduced dynamic model routing in Cortex AI Gateway, which automatically selects the most affordab…
